Seaport Therapeutics Raises $225 Million in Series B Financing

Seaport Therapeutics Raises $225 Million in Series B Financing

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On October 21, 2024, Seaport Therapeutics, a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, announced the closing of its $225 million Series B financing round. The financing was led by General Atlantic, a leading global growth investor, with participation from funds and accounts advised by T. Rowe Price Associates, Inc., Foresite Capital, Invus, Goldman Sachs Alternatives, CPP Investments and other new investors. Founding investors ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures and co-founder PureTech Health also participated. This latest round will help Seaport advance its clinical-stage pipeline of first and best-in-class medicines through important clinical milestones, along with further advancing its Glyph™ technology platform, which has demonstrated clinical proof-of-concept.

The WilmerHale team representing Seaport consisted of Stuart Falber, Riley O’Brien and Emily Ivers.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel